🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

59 results for “venetoclax” Clear

  1. Bactrim 160 mg + 800 mg compresse, CHLORPHENAMINE MALEATE, ALLOPURINOL, BRUKINSA 80 mg hard capsules, DEXAMETHASONE PHOSPHATE, VENETOCLAX, VENETOCLAX, Gazyvaro 1,000 mg concentrate for solution for infusion., Lamivudina Mylan 150 mg compresse rivestite con film, VENETOCLAX, PARACETAMOL

    Fondazione Telethon ETS

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  2. DARZALEX 20 mg/mL concentrate for solution for infusion, DARZALEX 1800 mg solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, VELCADE 3.5 mg powder for solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, Venetoclax, DEXAMETHASONE

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  3. Ivosidenib combined with venetoclax and azacitidine

    First Tracks Biotherapeutics

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  4. Ivosidenib, Venetoclax, Azacitidine

    China SXT Pharmaceuticals

    AML

    phase 2 small molecule active

    1 trial

  5. Jakavi 5 mg tablets, Venetoclax, Jakavi 20 mg tablets, Venetoclax, Jakavi 10 mg tablets, Venetoclax, Venetoclax, Venetoclax, Venetoclax, Jakavi 15 mg tablets

    AXIM BIOTECHNOLOGIES, INC.

    Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

    phase 2 small molecule active

    1 trial

  6. MBG453, VENETOCLAX, VENETOCLAX, AZACITIDINE, VENETOCLAX

    Novartis Ophthalmics Europe

    intermediate, high or very high risk MDS in adult patients chronic Myelomonocytic Leukemia - 2 (CMML-2) Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy

    phase 2 small molecule active

    1 trial

  7. Polivy 30 mg powder for concentrate for solution for infusion., Epcoritamab (GEN3013), Truxima 100 mg concentrate for solution for infusion, IMBRUVICA 140 mg hard capsules, Golcadomide, Revlimid 10 mg hard capsules, IMBRUVICA 140 mg hard capsules, PIRTOBRUTINIB, Cyclophosphamide Injection 500 mg., Venetoclax, Venetoclax, Epcoritamab (GEN3013), Revlimid 25 mg hard capsules, Venetoclax, Decortin® H 20 mg Tabletten, Truxima 500 mg concentrate for solution for infusion, Decortin® H 5 mg Tabletten, Adriblastin®

    AbbVie Deutschland GmbH & Co. KG

    B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma

    phase 2 small molecule active

    1 trial

  8. SPRYCEL 70 mg film-coated tablets, Venetoclax, SPRYCEL 100 mg film-coated tablets, Venetoclax, SPRYCEL 20 mg film-coated tablets, Venetoclax, SPRYCEL 50 mg film-coated tablets, Venetoclax, Venetoclax, Venetoclax, SPRYCEL 10 mg/mL powder for oral suspension

    AXIM BIOTECHNOLOGIES, INC.

    Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

    phase 2 small molecule active

    1 trial

  9. TAMBICICLIB 100 mg/10 mL, Solution for Injection, AZACITIDINE , TAMBICICLIB 100 mg/20 mL, Solution for Injection, VENETOCLAX

    Istituto Gentili S.r.l.

    Acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  10. VEN (Venetoclax)

    First Tracks Biotherapeutics

    Myelodysplastic Neoplasms

    phase 2 small molecule active

    1 trial

  11. VEN (Venetoclax)

    First Tracks Biotherapeutics

    Adult T-cell Leukemia/Lymphoma

    phase 2 small molecule active

    1 trial

  12. VENETOCLAX , Epcoritamab, Epcoritamab, VINCRISTINE , Jaypirca 100 mg film-coated tablets, DOXORUBICIN , Jaypirca 50 mg film-coated tablets, CYCLOPHOSPHAMIDE , PREDNISOLONE , LENALIDOMIDE , RITUXIMAB

    Genmab A/S

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  13. VENETOCLAX, VENETOCLAX, SY-1425, VENETOCLAX, AZACITIDINE

    Pharma Mar S.A.

    RARA-positive acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  14. VENETOCLAX, VENETOCLAX, VENETOCLAX, AZACITIDINE

    Fondazione Telethon ETS

    Acute Myeloid Leukemia with NPM1 mutation

    phase 2 small molecule active

    1 trial

  15. Venetoclax

    First Tracks Biotherapeutics

    Precursor B-Cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  16. Venetoclax

    First Tracks Biotherapeutics

    Early T Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  17. Venetoclax

    China SXT Pharmaceuticals

    FLT3 Gene Mutation

    phase 2 small molecule active

    1 trial

  18. Venetoclax

    First Tracks Biotherapeutics

    Acute Leukemia of Ambiguous Lineage

    phase 2 small molecule active

    1 trial

  19. Venetoclax

    Syndax Pharmaceuticals Inc

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  20. Venetoclax

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  21. Venetoclax monotherapy

    Adaptive Biotechnologies Corp

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule active

    1 trial

  22. Venetoclax, Azacitidine

    First Tracks Biotherapeutics

    T-cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  23. Venetoclax, Azacitidine

    China SXT Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 small molecule terminated

    1 trial

  24. Venetoclax, Venetoclax, Acalabrutinib, Venetoclax

    Ology Bioservices Ireland LTD

    Patients with relapsed CLL, Chronic lymphocytic leukemia

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources